55 results about "Virus infected cell" patented technology

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises, for example, a cell surface receptor polypeptide which is a cellular entry receptor for the entry of a virus into a host cell, which is linked to a polypeptide comprising an Fc region component. When the cell surface receptor polypeptide is an angiotensin converting enzyme 2 (ACE2) polypeptide or a fragment thereof, the immunotherapeutic protein is capable of binding to a coronavirus spike protein (S protein) and may be useful as an antiviral agent for the prevention or treatment of a coronavirus infection. The Fc region component may comprise an amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide which may enable the production of soluble oligomeric forms or the assembly of oligomeric forms from soluble monomeric forms upon binding to an S protein of a coronavirus (i.e. as present on a virion or the surface of virus-infected cells).

The invention discloses an Nfkb1 gene overexpression cell line and a construction method thereof, and relates to the field of gene engineering. The constructed recombinant lentiviral expression vector comprises a first LTR, a CMV promoter, an Nfkb1 gene, a Flag polypeptide tag, an EF-1a promoter, a green fluorescent protein gene, a shearing element, a screening gene and a nucleic acid fragment of a second LTR which are sequentially arranged from the 5'end to the 3 'end; co-transfecting a host cell by using the recombinant lentivirus expression vector and lentivirus packaging helper plasmid, and carrying out virus packaging to obtain an Nfkb1-overexpressed recombinant lentivirus; the HT22 cell line overexpressing the Nfkb1 is obtained by infecting the HT22 cell with the recombinant lentivirus overexpressing the Nfkb1, and screening the HT22 cell line overexpressing the Nfkb1 by using a resistance gene. Recombinant lentivirus is used as a vector, HT22 cells are infected with the recombinant lentivirus vector, a cell line capable of stably overexpressing the Nfkb1 gene is obtained through screening, and the effect of the Nfkb1 in neuroinflammation is conveniently researched.

The invention discloses a nano antibody for resisting a novel coronavirus mutant strain RBD structural domain antigen. The amino acid full-length sequence of the nano antibody is shown as any one of SEQ ID NO.5-8. The nano antibody disclosed by the invention has good capability of blocking the combination of a novel coronavirus mutant strain RBD and a receptor thereof, and can effectively prevent cells from being infected by viruses through experimental verification.

The invention discloses an application of Rottlerin in preparation of a medicine for preventing and treating nervous necrosis virus. According to the application disclosed by the invention, the fact that the rotinidin has high binding energy to RGNNV capsid protein is found, the rotinidin without toxic concentration is selected to carry out an RGNNV virus infected cell experiment, and the result shows that the rotinidin inhibits the replication of the RGNNV virus in a dose-dependent manner. The safe dosage of Rottlerin is obtained according to the survival rate of zebrafish treated with different doses, the influence of Rottlerin on the survival rate of zebrafish infected with RGNNV is researched, and finally it is proved that Rottlerin has a remarkable treatment effect on zebrafish infected with RGNNV. Rottlerin provides a new natural small molecule drug choice for prevention and treatment of VNN diseases, and has important research and development value and development significance for prevention and treatment of nervous necrosis viruses.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-15 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-15 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-15, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

Provided are a Dabie bandavirus mRNA vaccine and a preparation method therefor. Specifically an optimized mRNA molecule is provided, and is cloned into a pGEM-3Zf(+)mRNA vaccine vector; the plasmid is linearized by means of enzyme digestion, and subjected to capping and poly(A) tail addition by means of an in-vitro transcriptase method to prepare an mRNA; the obtained mRNA is transfected into eukaryotic cells, and it is verified by means of an immunoblotting experiment that the mRNA can be expressed in vitro; and the mRNA is encapsulated by a lipid nanoparticle delivery system to obtain the mRNA vaccine, which, after immunizing mice, can induce the generation of a relatively high antibody level in serum. A viral neutralization test further proves that the immune serum can bind to viruses to prevent the viruses from infecting cells.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-10 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-10 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-10, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

To provide methods and compositions for reducing virus titer and eliminating virus-infected cells from an individual.SOLUTION: Provided is the use of an anti-CD24 antibody in the production of medicament for use in a method for reducing hepatitis virus in an individual, where the method comprises: contacting the individual to a therapeutically effective dose of the anti-CD24 antibody for a period of time sufficient to reduce the amount of hepatitis virus, where the hepatitis virus is one or more of hepatitis B virus (HBV) and hepatitis delta virus (HDV).SELECTED DRAWING: None

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The present invention belongs to the field of biomedicine, and discloses a CAR-T cell that simultaneously targets BCMA and CD38 and secretes IL-15 and a preparation method thereof, the method comprising infecting T cells with a recombinant lentivirus, the recombinant lentivirus comprising a nucleic acid molecule encoding BCMA-CD38-IL15-CAR or being prepared by an expression vector comprising the nucleic acid molecule. The BCMA-CD38-IL15-CAR-T cell of the present invention can simultaneously target BCMA and CD38 and secrete IL-15, thereby improving the anti-tumor activity of CAR-T cells.

The application provides a benzene [d] isoxazole compound and an application thereof. The compound has the structure shown in the following formula I. The benzene [d] isoxazole compound provided by the application can induce degradation of BET protein and / or GSPT1 protein, and has an anti-proliferation effect on cancer cells. Therefore, the compound and the composition provided by the application can be used for preparing a drug for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and the like.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The application discloses a kind of targeted exosome chimeric antigen receptor molecules for treating HIV infection and its application, belong to the field of biological medicine technology.The application is packaged into targeted exosome by coding anti-HIV CAR mRNA directionally.The nano antibody sequence of targeted CD3, CD4, CD8+T receptor on T cell is fused to the N-terminal of LAMP-2B to construct specific targeting plasmid, so that the targeted peptide is expressed on the surface of exosome membrane, the expression plasmid containing RNA binding protein L7A and exosome tag protein CD63 is constructed, and the exosome loaded with CAR mRNA and targeted to T cell is obtained by three-plasmid co-transfection of HEK293F cells containing C / D box CAR plasmid.The exosome can construct human CAR-T cell when incubated with PBMC in vitro or back into humanized mouse in vivo, and has significant killing virus infected cell activity.

The present invention belongs to the field of biomedicine, and relates to a CAR-T cell expressing a dual-targeted CD38 and BCMA serial-parallel hybrid chimeric antigen receptor and secreting IL-10, and a preparation method thereof, the method comprising infecting T cells with a recombinant lentivirus, the recombinant lentivirus comprising a nucleic acid molecule encoding a dual-targeted CD38 and BCMA serial-parallel hybrid chimeric antigen receptor comprising IL-10, or obtained by an expression vector comprising the nucleic acid molecule. The CAR-T cell of the present invention expresses a serial-parallel hybrid CD38-BCMA-CAR and CD38-CAR, and can secrete the cytokine IL-10, promote the proliferation and effector function of CAR-T cells, and enhance anti-tumor activity.

The present disclosure relates to the field of methods for culturing virally-infected cells. More particularly, this disclosure relates to methods of culturing cells with an influenza A virus. The disclosure relates further to impact of certain culture factors such as trypsin concentration, pH levels, incubation time, and combinations thereof on the production of viral proteins, particularly haemagglutinin.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting CD38 and secreting IL-15 and a preparation method of the CAR-T cell, the method comprises the step of infecting the T cell with a recombinant lentivirus, and the recombinant lentivirus contains nucleic acid molecules encoding CD38-IL15-CAR or is prepared through an expression vector containing the nucleic acid molecules. The CD38-IL15-CAR-T cell disclosed by the invention expresses CD38-CAR, can secrete a cell factor IL-15, and can better enhance the survival and proliferation of effector cells such as natural killer cells and CD8 + T cells, so that the killing activity of the CAR-T cell on tumor cells is enhanced.

[Problem] To provide an antiviral oligonucleotide that acts on cells infected by viruses having multiple RNA genomes, exhibiting an antiviral effect, and does not tend to the emergence of resistant viruses, and a pharmacological composition thereof. [Solution] An oligonucleotide that takes on a G-quadruplex structure that inhibits the binding of the genomic RNA and nucleocapsid (N) protein of a virus having an RNA genome, the antiviral oligonucleotide suppressing proliferation of the virus by contact with virus-infected cells, and a pharmacological composition thereof are used.

The invention discloses a nano delivery system loaded with an activation module and an identification module and a preparation method and application thereof, and relates to the technical field of functional nano materials. The nano delivery system comprises nano gold particles, and an activation module and a targeted recognition module which are loaded on the nano gold particles at the same time. The nano-gold is used as a bridge, on one hand, the nano-gold is loaded with an NK cell activation module IL-15, and on the other hand, a nano-delivery system IL15-AuNPs-SA of a targeted recognition module SA antibody (taking new coronavirus infection as a model) of virus infected cells is loaded, so that on the premise of safely activating an immune system, the immune function of the immune system is enhanced, and the immune function of the immune system is enhanced. The effective screening and removing efficiency of the NK cells on virus infected cells is improved to the maximum extent.

The invention provides a PK-15 cell line capable of stably expressing porcine Mx2 protein as well as preparation and application of the PK-15 cell line. The PK-15 cell line capable of stably expressing porcine Mx2 gene is constructed through a lentiviral vector system. A specific primer is designed according to the nucleotide sequence of the porcine Mx2 gene in a GeneBank database, recombinant lentivirus plasmids are constructed after target genes are amplified, HEK293T cell packaging lentivirus is transfected by utilizing a three-plasmid system, PK-15 cells are infected by the obtained recombinant lentivirus, and the PK-15 cell line for stably expressing the porcine Mx2 gene is obtained through puromycin screening. Experimental results show that the PK-15 cell line PK-15-poMx2 capable of stably expressing the porcine Mx2 protein is successfully constructed by the method disclosed by the invention. Compared with normal PK-15 cells, the expression quantity of Mx2 in the porcine Mx2 stable expression cell line is remarkably increased, and the porcine Mx2 stable expression cell line has an inhibiting effect on replication of PRV (Porcine Reproductive Virus). Therefore, the successful construction of the cell line for stably expressing the porcine Mx2 protein provides an important tool for deeply exploring the functional characteristics and the antiviral action mechanism of the porcine Mx2 protein.

Methods for providing a vaccine composition capable of effectively inducing a systemic immune response and / or a topical immune response upon administration wherein the composition comprises a human leukocyte antigen class I (HLAI) restrictive epitope selected from the viral pathogen non-virion constituent protein (non-VIP) and thus elicits a CD8T cell response specific against viral infected cells.

A method for providing a vaccine composition capable of effectively inducing a systemic immune response and / or a local immune response upon administration, wherein the composition comprises a human leukocyte antigen class I (HLA I)-restricted epitope selected from viral pathogen non-viral particle constituent proteins (non-VIPs), and thus elicits a CD8 T cell response specific for virus-infected cells.

The application belongs to the technical field of biological medicine, and provides a recombinant type III human collagen peptide for resisting HPV infection and a preparation method and application thereof, an amino acid sequence of which is a coding sequence of positions 991-1032 of type III human collagen UniProtKB: P02461 repeated three times, named as ATHPV3, and an amino acid sequence of which is shown as SEQ ID NO. 1. After expression and purification, the recombinant type III human collagen peptide with a molecular weight of about 13 kD is obtained, can be specifically combined with HPV 16 / 18 L1 protein, has multiple hydrogen bond actions, and can inhibit pseudo-virus infection of 293T cells at high and medium concentrations. The application successfully obtains a recombinant type III human collagen peptide with good purity, which can be combined with HPV 16 / 18 L1 and can effectively inhibit HPV 16 / 18 pseudo-virus infection of 293T cells, and provides an effective candidate drug for preventing and treating HPV infection.

Compositions, methods, and kits of small molecular weight agents are capable of binding and stimulating Fc-gamma-activated receptors to enhance humoral immune responses and immune effector cell responses by improving immune effector cell and / or antibody-based efficacy on pathogenic microorganisms as well as viral infected and dysregulated cells. These can be used to treat infectious diseases, cancer and other humoral immunosuppressive diseases. In addition, non-stimulating analogs capable of blocking Fc-gamma activated receptors can also be used to inhibit immune effector cell activation and inflammatory downstream mediators.

The application provides a kind of 2,6-piperidinedione derivatives and preparation method and application thereof.The compound has the structure shown in the following formula I, formula II or formula III:2,6-piperidinedione derivatives described in the application can induce the degradation of GSPT1 protein, and have cytotoxic effect on cancer cells.Therefore, the compound and composition provided by the application can be used for preparing drugs for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and other related diseases.

The present invention belongs to the field of biomedicine, and relates to a CAR-T cell expressing a serial-parallel hybrid chimeric antigen receptor dual-targeting CD38 and BCMA and secreting IL-15, and a preparation method thereof, the method comprising infecting T cells with a recombinant lentivirus, the recombinant lentivirus comprising a nucleic acid molecule encoding a serial-parallel hybrid chimeric antigen receptor dual-targeting CD38 and BCMA and comprising IL-15, or obtained by an expression vector comprising the nucleic acid molecule. The CAR-T cell of the present invention expresses a serial-parallel hybrid CD38-BCMA-IL15-CAR and CD38-CAR, and can secrete the cytokine IL-15, which can better enhance the activation of natural killer cells and CD8 + The survival and proliferation of effector cells such as T cells can be enhanced, thereby enhancing the ability of CAR-T cells to kill tumor cells.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting CD38 and secreting IL-10 and a preparation method of the CAR-T cell, the method comprises the step of infecting the T cell with a recombinant lentivirus, and the recombinant lentivirus contains nucleic acid molecules encoding CD38-IL10-CAR or is prepared through an expression vector containing the nucleic acid molecules. The CD38-IL10-CAR-T cell disclosed by the invention expresses CD38-CAR and can secrete a cell factor IL-10, so that the proliferation of the terminal depleted CD8 < + > T cell is promoted and the tumor killing activity is improved.

The invention provides a preparation method of a lymphoma autologous tumor vaccine with high expression of TRIM-21, which comprises the following steps: amplifying a TRIM-21 gene from EL-4 cells through a PCR (Polymerase Chain Reaction) method, cloning the TRIM-21 gene into a lentiviral vector to construct a recombinant lentivirus, infecting the EL-4 cells with the recombinant lentivirus to obtain a lymphoma cell line with high expression of TRIM-21, and carrying out irradiation inactivation to obtain the lymphoma autologous tumor vaccine with high expression of TRIM-21. The lymphoma autologous tumor vaccine is obtained. The lymphoma cell line with high expression of TRIM-21 is prepared for the first time, and the lymphoma autologous tumor vaccine is prepared from the lymphoma cell line. A mouse tumor model verifies that the vaccine efficiently activates CD8 + T cell immune response and has an obvious tumor immunoprophylaxis effect, so that the vaccine can be applied to the field of preparation of tumor immunoprophylaxis drugs.

A method of culturing cells for vaccine production comprises culturing cells in the presence of microcarriers with cell culture media and infecting the cells with a virus. The microcarrier comprises a bead and a coating. The coating comprises a thermo-responsive polymer having a lower critical solution temperature (LCST) of between about 20 °C and about 34 °C. The cells adhere to the coating of the microcarrier at a temperature above the LCST. The microcarrier comprises a polymeric bead, and a hydrophobic polymer. The hydrophobic polymer is a block copolymer which is connected to the bead by a covalent bond or by physical adsorption. The block copolymer comprises at least one hydrophobic block and at least one thermo-responsive block.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.